About this trial
The study focuses the mechanisms underlying the loss of intestinal homeostasis in celiac disease, refractory celiac disease and other immune diseases such as monogenic enteropathy, inflammatory bowel diseases or drug induced intestinal diseases. Mechanisms of transformation of lymphocytes leading to onset of lymphomatous complications of immune enteropathies will be investigated. Mechanisms of loss of hepatic lymphocytic homeostasis will also be assessed in liver associated diseases.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
18 years or over
affiliated to social insurance
signed informed consent
Disqualifiers
pregnancy
under guardianship
not able to sign informed consent
Trial population
Patients planned to have blood specimens and possible upper and/or lower digestive endoscopy.
Trial design
Cohort
Prospective
Treatments tested in this trial
Blood sample collection; gastrointestinal biopsy
GeneticTargeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
Treatment groups
7
Treatment groupsSee each treatment group below.
Trial outcomes
Primary outcomes
Intestinal Lymphocytes count
Lymphocytes isolation
DNA sequencing
Targeted Next Generation sequencing
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Institut National de la Santé Et de la Recherche Médicale, France
Lead sponsor
Imagine Institute
Collaborator